España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Heather Behanna
Achaogen's Phase 3 Shows 'Best Case Scenario'
Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive
A Primer On Endpoints: Global Blood Therapeutics
Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive
A Primer On Endpoints: Global Blood Therapeutics
What To Expect From Catabasis Pharma's Proof Of Concept Study
Wedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51
What To Expect From Catabasis Pharma's Proof Of Concept Study
Wedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51
DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta
The Search For Silver Linings In The Cloud Of Negative Novavax News
Read More...
Heather Behanna Recent News
Wedbush Answers 'So, Now What?' For Novavax Shareholders
Need For New Drug Trial Increases Long-Term Risk For PTC Therapeutics, Says Wedbush
Wedbush Bullish On Sarepta's Eteplirsen Data
Achaogen Shares Upgraded To Outperform By Wedbush Following Optimistic Survey
Wedbush Upgrades Sarepta To Outperform As 'FDA Comes Up With Option C'
Wedbush Initiates Coverage On Cubist Pharmaceuticals
UPDATE: Wedbush Initiates Coverage On Tetraphase Pharmaceuticals On Room To Grow
UPDATE: Wedbush Initiates Coverage On Achaogen On High Clinical Risk
UPDATE: Wedbush Assumes Coverage On Noravax, Inc. As Stock Gears Up For Catalyst-Rich 2015
UPDATE: Wedbush Securities Initiates Coverage On Mirati Therapeutics, Inc. As Key Data Is Around The Corner
